BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CereSpir Incorporated is Pleased With Positive Interim Phase 2 Results for CHF 5074 in Patients With Mild Cognitive Impairment, Presented by Chiesi Farmaceutici SpA at the AAIC 2013 Meeting in Boston


7/26/2013 9:53:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated announced positive interim clinical results from Chiesi Farmaceutici's Phase 2 study testing CHF 5074, a novel, first-in-class small molecule microglia modulator, in patients with mild cognitive impairment (MCI). The 90-week study, which included a 96-patient 14-week double-blind, placebo-controlled study and an ongoing 76-week open-label extension study, tested three titrated doses of CHF 5074 (200 mg, 400 mg, 600 mg dosed orally once daily) in MCI patients. Upon completion of the 14-week study,

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES